- Correction of chart "Change on Year"-
2007: Sales EUR28.0 million, EBITDA EUR5.1 million, Net Profit for
year EUR1.5 million
Q1/2008: Sales c. EUR8.0 million
aap Implantate AG, a medical technology company listed on the
Frankfurt stock exchange and active in biomaterials, fracture healing
and joint replacement, achieved in financial year 2007 sales growth
of 52% to EUR28.0 million (previous year: EUR18.5 million) and an
operating result (EBIT) of EUR3.0 million (+36% on the previous
year). Net profit for the year was slightly down by EUR0.1 million to
EUR1.5 million (previous year: EUR1.6 million) due to one-off
deferred tax expenses with no effect on liquidity. The aap group
achieved this growth by means of organic growth in the T&O segment
(Sales +26% to EUR7.8 million) and by first-time consolidation of
Dutch Fame Medical Group acquisition as well as organic growth in the
medical biomaterials segment (aap bio implants group, sales +65% to
EUR20.2 million), which generated over 70% of overall aap sales in
2007.
+-------------------------------------------------------------------+
| In EUR million | 2007 | 2006 excl. aap | Change on |
| | | NL | year |
|---------------------+------------+----------------+---------------|
| Sales | 28.0 | 18.5 | +52% |
|---------------------+------------+----------------+---------------|
| EBITDA | 5.1 | 3.9 | +31% |
|---------------------+------------+----------------+---------------|
| EBIT | 3.0 | 2.2 | +36% |
|---------------------+------------+----------------+---------------|
| EBT | 2.4 | 2.1 | +14% |
|---------------------+------------+----------------+---------------|
| Net profit for year | 1.5 | 1.6 | -6% |
|---------------------+------------+----------------+---------------|
| Equity (ratio) | 43.4 (64%) | 21.2 (77%) | +101% |
|---------------------+------------+----------------+---------------|
| Total assets | 68.0 | 27.6 | +143% |
|---------------------+------------+----------------+---------------|
| Employees | 289 | 161 | + 80% |
+-------------------------------------------------------------------+
In financial year 2007 the aap group of companies earned a
significantly higher EBITDA of EUR5.1 million (previous year: EUR3.9
million).
Group EBIT improved to EUR3.0 million (previous year: EUR2.2
million). EBT amounted to EUR2.4 million and was also up on the
previous year's EUR2.1 million.
With total assets of EUR68.0 million (previous year: EUR27.6 million)
the equity ratio was 64%.
According to preliminary calculations aap group sales in the first
quarter of 2008 were in the region of EUR8.0 million, or around 35%
than the ¤5.9 million in the same quarter of the previous year. This
organic sales growth year on year was due to triple-digit percental
sales growth by the Trauma & Orthopaedics division, due to the
delivery of an initial order to a major OEM customer amongst others.
For the financial year 2008 aap anticipates a continuation of this
growth trend and aims to achieve organic sales growth of at least 20%
and above-average earnings growth.
The consolidated annual financial statements of aap Implantate AG are
available to download at www.aap.de. Publication of the report for
the first quarter of 2008 is scheduled for May 14, 2008.
-
aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotic carriers, and implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main as well as
at Nijmegen in the Netherlands. aap Implantate AG has been listed in
the Prime Standard segment at the Frankfurt stock exchange since May
16, 2003.
Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Head of Corporate
Communications, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de
For further information about aap bio implants, visit
www.aap-bioimplants.com